Sugi Predict

Sugi Predict / Targets / CXCL12

CXCL12

Stromal cell-derived factor 1 · P48061 · CXCL12 on Sugi Atlas →

16,030 patent compounds predicted against CXCL12, 12,142 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL597849 SCHEMBL597849 0.82 10/20
SCHEMBL597850 SCHEMBL597850 0.82 10/20
Formaldehyde Formaldehyde (SCHEMBL597329) 0.78 10/20
SCHEMBL597330 SCHEMBL597330 0.48 7/20
SCHEMBL1098000 SCHEMBL1098000 0.56 6/20
SCHEMBL1098002 SCHEMBL1098002 0.56 6/20
SCHEMBL1225523 SCHEMBL1225523 0.69 5/20
SCHEMBL1225524 SCHEMBL1225524 0.69 5/20
SCHEMBL995788 SCHEMBL995788 0.48 5/20
SCHEMBL995789 SCHEMBL995789 0.48 5/20
SCHEMBL996603 SCHEMBL996603 0.48 5/20
SCHEMBL996606 SCHEMBL996606 0.48 5/20
SCHEMBL996587 SCHEMBL996587 0.47 5/20
SCHEMBL996590 SCHEMBL996590 0.47 5/20
Ferulate Ferulate (SCHEMBL972445) 0.76 4/20
SCHEMBL363641 SCHEMBL363641 0.59 4/20
SCHEMBL363972 SCHEMBL363972 0.58 4/20
SCHEMBL815466 SCHEMBL815466 0.55 4/20
SCHEMBL996824 SCHEMBL996824 0.51 4/20
SCHEMBL996825 SCHEMBL996825 0.51 4/20

Clinical trials — most relevant to CXCL12 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Effect of Vildagliptin Versus Dapagliflozin as Add on Therapy to Metformin on Cardiovascular Risk Factors PHASE4COMPLETED
Stem Cell Mobilization With Plerixafor in Diabetic vs Control Subjects PHASE4COMPLETED
Functional Improvement of Progenitor Cells and Endothelial Function by Vildagliptin in Diabetes Mellitus (FINNjA-DM). PHASE2/PHASE3WITHDRAWN
Safety Study of a Chemokine Receptor (CXCR4) Antagonist in Multiple Myeloma Patients PHASE1/PHASE2COMPLETED
AMD 3100 (Mozobil Plerixafor) to Mobilize Stem Cells for Donation PHASE2COMPLETED
NOX-A12 in Combination With Bortezomib and Dexamethasone in Relapsed Multiple Myeloma PHASE2COMPLETED
Chemosensitization With Plerixafor Plus G-CSF in Acute Myeloid Leukemia PHASE1/PHASE2COMPLETED
NOX-A12 in Combination With Bendamustine and Rituximab in Relapsed Chronic Lymphocytic Leukemia (CLL) PHASE2COMPLETED
Quantitating the Impact of Plerixafor PHASE1/PHASE2UNKNOWN
Combination of G-CSF, Bortezomib, Cyclophosphamide and Dexamethasone in Patients With Multiple Myeloma PHASE2UNKNOWN
AMD3100 Plus Mitoxantrone, Etoposide and Cytarabine in Acute Myeloid Leukemia PHASE1/PHASE2COMPLETED
Chemo Sensitization Before Hematopoietic Stem Cell Transplantation in Patients With Acute Leukemia in Complete Remission PHASE2UNKNOWN
Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models PHASE2RECRUITING
Trial of X4P-001 in Participants With Advanced Renal Cell Carcinoma PHASE1/PHASE2COMPLETED
The Effectiveness of Allogenic Mesenchymal Stem Cells Therapy on Hair Regrowth in Androgenetic Alopecia. PHASE1/PHASE2ENROLLING_BY_INVITATION
Plerixafor and Granulocyte Colony-stimulating Factor (G-CSF) in Combination With Azacitidine for the Treatment of Myelodysplastic Syndrome (MDS) PHASE1COMPLETED
POETIC Plerixafor as a Chemosensitizing Agent for Relapsed Acute Leukemia and MDS in Pediatric Patients PHASE1COMPLETED
An Evaluation of Safety and Efficacy of Escalating Doses of AMD3100 to Mobilize CD34+ Cells in Healthy Volunteers PHASE1COMPLETED
X4P-001 and Pembrolizumab in Patients With Advanced Melanoma PHASE1COMPLETED
A Phase 1 Study to Evaluate Paclitaxel Conjugated CXC Receptor 4 Antagonist (MB1707) in Patients With Advanced Cancer EARLY_PHASE1WITHDRAWN
Bayraktutan Dunhill Medical Trust EPC Study nanUNKNOWN
Mesenchymal Stem Cells in NPM1 Mutated Low Risk Acute Myeloid Leukemia: a Study of the Tumor Microenvironment and Its Contribution to the Outcome nanCOMPLETED
Observational Study to Evaluate Hematopoietic Progenitor Cell Mobilization in Patients With Newly Diagnosed Multiple Myeloma nanCOMPLETED
The Role of Stromal Cell-Derived Factor-1 (SDF-1)/CXC Chemokine Receptor 4 (CXCR4) in Metastasis of Laryngeal and Hypopharyngeal Squamous Cell Carcinoma nanUNKNOWN
C-X-C Chemokine Receptor 4 in Chronic Lymphocytic Leukemia nanUNKNOWN
Involvement of Skeletal Muscle Fibrocytes in sarcOpenia in Patients With Chronic ObstRuctive Pulmonary Disease nanCOMPLETED
The Role of MMPs in the CXCL12-Induced Invasion of Laryngeal and Hypopharyngeal Squamous Cell Carcinoma nanUNKNOWN
Prospective Observational Study on Plerixafor After Chemotherapy nanCOMPLETED
The Role of SDF-1/CXCR4 in Metastasis of Oral Squamous Cell Carcinoma nanUNKNOWN
Studies on the Significance of CXCR4-CXCL12 on Leukemic Cells Passing ThroughMarrow-Blood Barrier nanUNKNOWN

Related proteins — ESM-2 sequence neighbours (a CXCL12 binder may also engage these)

ProteinNameSimilarity
O62657 — 0.999 O62657 →
P40224 — 0.998 P40224 →
Q9GKY0 — 0.900 Q9GKY0 →
Q58D84 — 0.896 Q58D84 →
O14625 — 0.896 O14625 →
Q62356 — 0.896 Q62356 →
Q5R9Y1 — 0.895 Q5R9Y1 →
Q12841 — 0.895 Q12841 →
Q5R8Y5 — 0.892 Q5R8Y5 →
Q62632 — 0.892 Q62632 →
A8MXK1 — 0.892 A8MXK1 →
Q9H6U8 — 0.891 Q9H6U8 →
Q8BTQ0 — 0.890 Q8BTQ0 →
Q08334 — 0.890 Q08334 →
Q96E11 — 0.890 Q96E11 →
Q0VCQ4 — 0.889 Q0VCQ4 →
Q5RKI9 — 0.888 Q5RKI9 →
NCEH1 Neutral cholesterol ester hydrolase 1 0.888 landscape →
Q1JQE6 — 0.887 Q1JQE6 →
Q8VDI9 — 0.887 Q8VDI9 →
Q90986 — 0.887 Q90986 →
Q3KNV8 — 0.885 Q3KNV8 →
Q8BLF1 — 0.885 Q8BLF1 →
Q96NT3 — 0.885 Q96NT3 →
P55244 — 0.885 P55244 →
Q2KJ29 — 0.885 Q2KJ29 →
Q06922 — 0.885 Q06922 →
Q62956 — 0.884 Q62956 →
Q8BZI6 — 0.883 Q8BZI6 →
ERBB4 Receptor tyrosine-protein kinase erbB-4 0.883 landscape →